Article
Gastroenterology & Hepatology
Adrian Vallejo, Oihane Erice, Rodrigo Entrialgo-Cadierno, Iker Feliu, Elizabeth Guruceaga, Maria J. Perugorria, Paula Olaizola, Alexandra Muggli, Irati Macaya, Michael O'Dell, Borja Ruiz-Fernandez De Cordoba, Sergio Ortiz-Espinosa, Aram F. Hezel, Imanol Arozarena, Fernando Lecanda, Matias A. Avila, Maite G. Fernandez-Barrena, Matthias Evert, Mariano Ponz-Sarvise, Diego F. Calvisi, Jesus M. Banales, Silve Vicent
Summary: The transcription factor FOSL1 plays a crucial role in the development and progression of cholangiocarcinoma (CCA), and its downstream effectors are susceptible to pharmacological inhibition, providing new opportunities for therapeutic intervention in CCA.
JOURNAL OF HEPATOLOGY
(2021)
Review
Pharmacology & Pharmacy
Fatemeh Yarmohammadi, Ramin Rezaee, A. Wallace Haye, Gholamreza Karimi
Summary: Doxorubicin is a chemotherapeutic agent with dose-dependent cardiotoxicity, which can lead to arrhythmia and heart failure. Studies have shown that induction of endoplasmic reticulum stress signaling pathways may contribute to cardiac complications induced by Doxorubicin.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Oncology
Manuela Mancini, Cecilia Monaldi, Sara De Santis, Cristina Papayannidis, Michela Rondoni, Chiara Sartor, Samantha Bruno, Livio Pagano, Marianna Criscuolo, Roberta Zanotti, Massimiliano Bonifacio, Patrizia Tosi, Michel Arock, Peter Valent, Michele Cavo, Simona Soverini
Summary: Proteasome inhibitors can suppress cell growth and induce apoptosis in neoplastic mast cells by promoting SETD2/H3K36Me3 re-expression. Aurora kinase A and MDM2 are implicated in SETD2 loss of function in AdvSM. Targeting Aurora A or proteasome inhibitors may have therapeutic potential in AdvSM treatment.
BIOMARKER RESEARCH
(2023)
Article
Oncology
David K. Lau, Ian Y. Luk, Laura J. Jenkins, Andrew Martin, David S. Williams, Kael L. Schoffer, Fiona Chionh, Michael Buchert, Katrin Sjoquist, Alex Boussioutas, Sarah A. Hayes, Matthias Ernst, Andrew J. Weickhardt, Nick Pavlakis, Niall C. Tebbutt, John M. Mariadason
Summary: Amplification or overexpression of the FGFR family is a common occurrence in gastric cancer, with the multikinase inhibitor Regorafenib showing sensitivity in FGFR-driven gastric cancer cell lines. However, the limited clinical response to Regorafenib in the INTEGRATE trial cohort suggests a potential reactivation of MAPK/ERK signaling, which can be overcome by combinatorial inhibition of FGFR and MEK for more effective treatment of FGFR-driven gastric cancers.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Obstetrics & Gynecology
Zehra Ordulu, Stefanie Avril, Valentina Nardi, Dora Dias-Santagata, Esther Oliva
Summary: The molecular knowledge of endometrial stromal neoplasms is important for their better categorization. Low-grade endometrial stromal sarcomas commonly have JAZF1-SUZ12 fusion, while those with sex cord-like differentiation are more likely to have PHF1 fusions. Fluorescence in situ hybridization may have limitations in detecting fusions.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
(2022)
Article
Oncology
Ramachandra Katabathula, Peronne Joseph, Salendra Singh, Songzhu Zhao, Bhavna Kumar, Patricia Gaule, Quintin Pan, Matthew Old, David P. Tuck, Vinay Varadan
Summary: This study investigated the expression and clinical significance of VSIR in tumors. It found that VSIR overexpression in oral cavity and ovarian cancers was associated with poorer overall survival and decreased CD4 helper T-cell activity. VSIR overexpressing tumors also exhibited higher STAT3 signaling activity. The findings suggest that the STAT3-VSIR axis may play a significant role in the immune response of these types of cancer.
CLINICAL CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Akihiro Yoshida, Polly Phillips-Mason, Vincenzo Tarallo, Stefanie Avril, Christopher Koivisto, Gustavo Leone, J. Alan Diehl
Summary: Cyclin D1 is a protein that regulates the progression of the cell cycle. Its phosphorylation at threonine 286 is necessary for degradation, and mutations at this site can lead to genomic instability and tumor development. Previous studies using artificial promoters may not accurately reflect the tumorigenic functions of mutant cyclin D1. In this study, a conditional knock-in mouse model was used to show that mutation at threonine 286 of cyclin D1 plays a critical role in regulating inflammation and tumor development.
Article
Biochemical Research Methods
Sirvan Khalighi, Peronne Joseph, Deepak Babu, Salendra Singh, Thomas LaFramboise, Kishore Guda, Vinay Varadan
Summary: SYSMut is an extendable systems biology platform that can infer the biological consequences of gene mutations by integrating multiomics profiles. It has been used to identify driver genes across 29 cancers and discover new therapeutic targets in head and neck squamous cell cancer.
BRIEFINGS IN BIOINFORMATICS
(2022)
Article
Environmental Sciences
Anna Kimberly Miller, Jennifer Catherine Gordon, Jacqueline W. Curtis, Jayakrishnan Ajayakumar, Fredrick R. Schumacher, Stefanie Avril
Summary: This study explores the geographic patterns of EC patients within a US institutional cancer registry, finding that patients with non-endometrioid histotypes exhibit geographic clustering in their home address. Living in a high social vulnerability area is associated with non-endometrioid histotypes. The study provides a methodological framework for early targeted intervention and fills the knowledge gap of geography in gynecologic cancers.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Article
Oncology
Leslie Cuellar-Vite, Kristen L. Weber-Bonk, Fadi W. Abdul-Karim, Christine N. Booth, Ruth A. Keri
Summary: This study discovered that blocking FAK can improve the therapeutic response to mTORC1 inhibitors in resistant breast cancer. It suggests a potential strategy of dual targeting FAK and mTORC1.
Article
Oncology
Lindsey J. Anstine, Parth R. Majmudar, Amy Aponte, Salendra Singh, Ran Zhao, Kristen L. Weber-Bonk, Fadi W. Abdul-Karim, Mitchell Valentine, Darcie D. Seachrist, Katelyn E. Grennel-Nickelson, Leslie Cuellar-Vite, Gina M. Sizemore, Steven T. Sizemore, Bryan M. Webb, Cheryl L. Thompson, Ruth A. Keri
Summary: Breast cancer subtypes and their phenotypes correspond to different stages of mammary epithelial cell development. The discovery of mechanisms that control lineage identity may offer new opportunities for reducing disease progression. This study reveals that the transcriptional corepressor TLE3 functions as a guardian of luminal cell fate in breast cancer, independent of the estrogen receptor. TLE3 represses the gene-expression signature associated with aggressive basal-like breast cancers, thereby reducing metastatic capacity and aggressive behaviors.
Review
Endocrinology & Metabolism
Jessica R. Bobbitt, Darcie D. Seachrist, Ruth A. Keri
Summary: The development of sequencing technologies has provided valuable information about the organization of the 3-dimensional genome and its influence on cancer progression. Chromatin folding and accessibility changes can lead to abnormal transcriptional programs and drive the development of various cancers, including different subtypes of breast cancer. Understanding the chromatin architecture in breast cancer subtypes can help define their phenotypic characteristics and identify potential targets for aggressive disease treatment.
Meeting Abstract
Oncology
Sachin Patnaik, Cassandra Gilmour, Stefanie Avril, Andrelie Branicky, Ajay Zalavadia, Judith Drazba, Li Wang
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Meeting Abstract
Oncology
Arpit Aggarwal, Sepideh Azarianpour-Esfahani, Haojia Li, Pingfu Fu, Mojgan Mokhtari, Stefanie Avril, Haider Mahdi, Anant Madabhushi
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Meeting Abstract
Oncology
Rebecca Deasy, Xin Jin, Pierre Michel Jean Beltran, Adel Atari, Madison Liistro, Cheryl Thompson, Stefanie Avril, Julie Boerner, Payal Pradhan, Samuel Klempner, Keith Ligon, William Sellers, Steven Carr, Todd Golub, Yuen-Yi (Moony) Tseng
Meeting Abstract
Oncology
Jennifer Gordon, Sadhvi Batra, Sahana Kannan, Stefanie Avril, Fredrick Schumacher
GYNECOLOGIC ONCOLOGY
(2022)
Meeting Abstract
Oncology
Jennifer Gordon, Jacqueline Curtis, Olga Kovalenko, Anna Miller, Jayakrishnan Ajayakumar, Stacy Smrz, Fredrick Schumacher, Stefanie Avril
GYNECOLOGIC ONCOLOGY
(2022)
Meeting Abstract
Oncology
Stacy Smrz, Jennifer Gordon, Fredrick Schumacher, Jayakrishnan Ajayakumar, Anna Miller, Stefanie Avril, Jacqueline Curtis
GYNECOLOGIC ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Yihong Guan, Metis Hasipek, Dongxu Jiang, Anand D. Tiwari, Dale R. Grabowski, Simona Pagliuca, Sunisa Kongkiatkamon, Bhumika Patel, Salendra Singh, Yvonne Parker, Thomas LaFramboise, Daniel Lindner, Mikkael A. Sekeres, Omar Y. Mian, Yogen Saunthararajah, Jaroslaw P. Maciejewski, Babal K. Jha
Summary: Eltrombopag binds to the TET2 catalytic domain and inhibits its dioxygenase activity, leading to the expansion of normal hematopoietic stem cells and the prevention of neoplastic evolution in TET2 mutant malignant myeloid cells. This finding provides a scientific rationale for the treatment of myeloid malignancies associated with TET2 mutations or TET deficiency.
JOURNAL OF CLINICAL INVESTIGATION
(2022)